{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T02:46:39Z","timestamp":1770345999780,"version":"3.49.0"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Immune checkpoint inhibitors (ICIs) have revolutionised the cancer treatment landscape in the last decades, improving the outcome of several tumours, such as cutaneous squamous cell carcinoma (cSCC). ICIs are antibodies blocking several immune checkpoint pathways, as cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) with its ligand PD-L1. However, the activation of immune response can cause a broad range of side effects, called immune-related adverse events (irAEs). Endocrine irAEs are mainly represented by thyroid dysfunctions (thyrotoxicosis or hypothyroidism) and hypophysitis, while adrenal insufficiency and diabetes mellitus (DM) are less common. Diabetic ketoacidosis (DKA) is a potential life-threatening presentation of ICI-induced insulin-dependent DM (IDDM). This report presents a rare case of DKA and IDDM secondary to anti-PD-1 antibody cemiplimab therapy, and this is the third described in the literature to date.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>We describe the case of a 62-year-old female patient with metastatic perianal squamous cell carcinoma who developed DKA and IDDM after the fifth cycle of cemiplimab. Hyperglycemia (1187 mg\/dL), metabolic acidosis (pH 7.27) with bicarbonate levels of 11.9 mmol\/L, arterial partial pressure of carbon dioxide of 25.7 mmHg with increased anion gap (equal to 25), and hyperketonuria were present. Adequate glycaemic control was difficult to maintain, and intravenously therapy (insulin, sodium bicarbonate, potassium, and fluids) was required for a long time. Subcutaneous basal-bolus insulin treatment was started, but glycaemic control was scarce, also due to the concomitant administration of prednisone for immune-related hepatotoxicity, until the subject\u2019s death.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This report underlines the importance of the awareness on endocrine irAEs with ICIs, particularly life-threatening DKA. A baseline assessment of glycemia and glycated hemoglobin is mandatory, and we recommend a close monitoring of glycemic trend over time during ICIs therapy. Patients and their caregivers should be informed and counselled to recognise DKA signs and symptoms.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1550702","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T06:50:01Z","timestamp":1742885401000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Cemiplimab and diabetic ketoacidosis: a case report of a rare endocrinopathy associated with immune checkpoint inhibitors"],"prefix":"10.3389","volume":"16","author":[{"given":"Anna","family":"Arecco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristian","family":"Petolicchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Pastorino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrica Teresa","family":"Tanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Vera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara","family":"Boschetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Cocchiara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide Carlo","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Ferone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0190","article-title":"T-cell\u2013based immunotherapy: adoptive cell transfer and checkpoint inhibition","volume":"3","author":"Houot","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-021-00833-8","article-title":"A review of cancer immunotherapy toxicity: immune checkpoint inhibitors","volume":"17","author":"Chhabra","year":"2021","journal-title":"J Med Toxicol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1012-5","article-title":"Cemiplimab: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.574271","article-title":"The use of immune checkpoint inhibitors in oncology and the occurrence of AKI: where do we stand","volume":"11","author":"Franzin","year":"2020","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers"},{"key":"B8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3892\/ol.2024.14803","article-title":"PD\u22121\/PD\u2212L1 inhibitor\u2212based immunotherapy in locally advanced or metastatic triple\u2212negative breast cancer: A meta\u2212analysis","volume":"29","author":"Chen","year":"2024","journal-title":"Oncol Lett"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03520-5","article-title":"PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies","volume":"72","author":"Lin","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184705","article-title":"Current landscape of non-small cell lung cancer: epidemiology, histological classification, targeted therapies, and immunotherapy","volume":"13","author":"Rodak","year":"2021","journal-title":"Cancers"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2022.101418","article-title":"Diabetic ketoacidosis","volume":"69","author":"Calimag","year":"2023","journal-title":"Disease-a-Month"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-9909","article-title":"Diabetic ketoacidosis in infants, children, and adolescents","volume":"29","author":"Wolfsdorf","year":"2006","journal-title":"Diabetes Care"},{"key":"B15","doi-asserted-by":"publisher","first-page":"l1114","DOI":"10.1136\/bmj.l1114","article-title":"Diabetic ketoacidosis and hyperosmolar hyperglycemic syndrome: review of acute decompensated diabetes in adult patients","volume":"365","author":"Karslioglu French","year":"2019","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e24372","DOI":"10.7759\/cureus.24372","article-title":"Steroid-induced diabetic ketoacidosis: A case report and review of the literature","volume":"14","author":"Cavataio","year":"2022","journal-title":"Cureus"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00023210-200519001-00001","article-title":"Second-generation (Atypical) antipsychotics and metabolic effects: A comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e26267","DOI":"10.7759\/cureus.26267","article-title":"SGLT-2 inhibitor-associated euglycemic diabetic ketoacidosis: A case report and a literature review","volume":"14","author":"Mahfooz","year":"2022","journal-title":"Cureus"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00014","article-title":"Immune checkpoint inhibitor-induced diabetic ketoacidosis: A report of four cases and literature review","volume":"11","author":"Hong","year":"2020","journal-title":"Front Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.hoc.2018.08.001","article-title":"Cutaneous squamous cell carcinoma","volume":"33","author":"Waldman","year":"2019","journal-title":"Hematology\/Oncology Clinics North America"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042320-120056","article-title":"Cutaneous squamous cell carcinoma: the frontier of cancer immunoprevention","volume":"17","author":"Chang","year":"2022","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209813","article-title":"Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma","volume":"387","author":"Gross","year":"2022","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211060523","article-title":"Diabetic ketoacidosis as a hallmark of autoimmune diabetes occurring after two cycles of cemiplimab","volume":"28","author":"Jouneghani","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e60565","DOI":"10.7759\/cureus.60565","article-title":"Cemiplimab-induced hyperosmolar hyperglycemic state with concurrent diabetic ketoacidosis in a patient receiving treatment for cutaneous squamous cell carcinoma","volume":"15","author":"Pyronneau","year":"2024","journal-title":"Cureus"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"De Filette","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e000591","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.endien.2022.06.013","article-title":"Abrupt-onset diabetes mellitus secondary to pembrolizumab","volume":"70","author":"Pastor Alcaraz","year":"2023","journal-title":"Endocrinolog\u00eda Diabetes y Nutrici\u00f3n (English ed)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e253696","DOI":"10.1136\/bcr-2022-253696","article-title":"Immune checkpoint inhibitor-induced diabetes mellitus with nivolumab","volume":"16","author":"Zand Irani","year":"2023","journal-title":"BMJ Case Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00423","article-title":"Checkpoint inhibitor\u2013associated autoimmune diabetes is distinct from type 1 diabetes","volume":"104","author":"Tsang","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1157805","article-title":"Endocrine side effects of immune checkpoint inhibitors","volume":"14","author":"Cardona","year":"2023","journal-title":"Front Endocrinol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2023.0072","article-title":"Immune-checkpoint inhibitors-induced type 1 diabetes mellitus: from its molecular mechanisms to clinical practice","volume":"47","author":"Cho","year":"2023","journal-title":"Diabetes Metab J"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2518","article-title":"T-lymphocyte infiltration to islets in the pancreas of a patient who developed type 1 diabetes after administration of immune checkpoint inhibitors","volume":"42","author":"Yoneda","year":"2019","journal-title":"Diabetes Care"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2019743117","article-title":"Cytocidal macrophages in symbiosis with CD4 and CD8 T cells cause acute diabetes following checkpoint blockade of PD-1 in NOD mice","volume":"117","author":"Hu","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09618-w","article-title":"Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature","volume":"22","author":"Lo Preiato","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2022.101657","article-title":"Type 1 diabetes related to immune checkpoint inhibitors","volume":"36","author":"Tachibana","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2337\/db22-0557","article-title":"Inflammatory cell infiltration into islets without PD-L1 expression is associated with the development of immune checkpoint inhibitor\u2013related type 1 diabetes in genetically susceptible patients","volume":"72","author":"Kawata","year":"2023","journal-title":"Diabetes"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S002","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes\u20142025","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2020.100011","article-title":"How we treat endocrine complications of immune checkpoint inhibitors","volume":"6","author":"Paschou","year":"2021","journal-title":"ESMO Open"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"JCO"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-024-04050-5","article-title":"Pathophysiology, diagnosis, and management of immune checkpoint inhibitor-induced diabetes mellitus","volume":"87","author":"Kani","year":"2024","journal-title":"Endocrine"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Cancer Network"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ19-0163","article-title":"Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society","volume":"66","author":"Arima","year":"2019","journal-title":"Endocr J"},{"key":"B44","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J immunotherapy Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pky021","article-title":"The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management","volume":"2","author":"Girotra","year":"2018","journal-title":"JNCI Cancer Spectr"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06183-8","article-title":"Hyperglycaemic crises in adults with diabetes: a consensus report","volume":"67","author":"Umpierrez","year":"2024","journal-title":"Diabetologia"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1835-4","article-title":"A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome","volume":"65","author":"Hansen","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-018-1234-8","article-title":"Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype","volume":"56","author":"Marchand","year":"2019","journal-title":"Acta Diabetol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0908","article-title":"Successful treatment of immune checkpoint inhibitor\u2013induced diabetes with infliximab","volume":"42","author":"Trinh","year":"2019","journal-title":"Diabetes Care"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13927","article-title":"Recovery from insulin dependence in immune checkpoint inhibitor-associated diabetes mellitus: A case report","volume":"14","author":"Okubo","year":"2023","journal-title":"J Diabetes Invest"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-024-01077-6","article-title":"Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors","author":"Iwama","year":"2025","journal-title":"Nat Rev Endocrinol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1248919","article-title":"Nivolumab-induced diabetes mellitus\u2014a case report with literature review of the treatment options","volume":"14","author":"Daetwyler","year":"2023","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2018.12.014","article-title":"Comparison of outcomes and costs between adult diabetic ketoacidosis patients admitted to the ICU and step-down unit","volume":"50","author":"Fernando","year":"2019","journal-title":"J Crit Care"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2021-001901","article-title":"Comparing patient characteristics and outcomes in type 1 versus type 2 diabetes with diabetic ketoacidosis: A review and a propensity-matched nationwide analysis","volume":"69","author":"Shaka","year":"2021","journal-title":"J Invest Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-022-01953-5","article-title":"Mortality after discharge from hospital following an episode of diabetic ketoacidosis","volume":"59","author":"Shand","year":"2022","journal-title":"Acta Diabetol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06102-x","article-title":"Diabetes and infection: review of the epidemiology, mechanisms and principles of treatment","volume":"67","author":"Holt","year":"2024","journal-title":"Diabetologia"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0287","article-title":"Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study","volume":"41","author":"Critchley","year":"2018","journal-title":"Diabetes Care"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S004","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes\u20142025","volume":"48","author":"ElSayed","year":"2025","journal-title":". Diabetes Care"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-017-0740-9","article-title":"Polyglandular autoimmune syndromes","volume":"41","author":"Kahaly","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i32.5376","article-title":"Immune checkpoint inhibitor-related hepatotoxicity: A review","volume":"27","author":"Remash","year":"2021","journal-title":"WJG"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13746","article-title":"Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents","volume":"38","author":"Suzman","year":"2018","journal-title":"Liver Int"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J Hepatol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.06.036","article-title":"Metastatic cutaneous squamous cell carcinoma responsive to cemiplimab in a patient with multiple myeloma","volume":"6","author":"Marukian","year":"2020","journal-title":"JAAD Case Rep"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0191","article-title":"Infrequent liver injury from cemiplimab in patients with advanced cutaneous squamous cell carcinoma","volume":"14","author":"Swanson","year":"2022","journal-title":"Immunotherapy"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1303893","article-title":"Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report","volume":"14","author":"Passarelli","year":"2023","journal-title":"Front Immunol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1550702\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T06:50:04Z","timestamp":1742885404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1550702\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":65,"alternative-id":["10.3389\/fendo.2025.1550702"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1550702","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"article-number":"1550702"}}